Post-infection irritable bowel syndrome in the tropical and subtropical regions: Vibrio cholerae is a new cause of this well-known condition.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
   Guideline
2. Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice.BMC microbiology · 2023
   Article
3. Postinfection Irritable Bowel Syndrome.Gut and liver · 2022
   Review
4. Irritable bowel syndrome and microbiome; Switching from conventional diagnosis and therapies to personalized interventions.Journal of translational medicine · 2022
   Review
5. Post-infection functional gastrointestinal disorders following coronavirus disease-19: A case-control study.Journal of gastroenterology and hepatology · 2022
   Article
6. Pathophysiological mechanisms underlying gastrointestinal symptoms in patients with COVID-19.World journal of gastroenterology · 2021
   Review
7. Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine.Journal of neurogastroenterology and motility · 2021
   Article
8. Global burden of irritable bowel syndrome: trends, predictions and risk factors.Nature reviews. Gastroenterology & hepatology · 2020
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as